Onco-nephrology: tumor lysis syndrome.

  title={Onco-nephrology: tumor lysis syndrome.},
  author={F Perry Wilson and Jeffrey S. Berns},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  volume={7 10},
Tumor lysis syndrome (TLS) describes the clinical and laboratory sequelae that result from the rapid release of intracellular contents of dying cancer cells. It is characterized by the release of potassium, phosphorous, and nucleic acids from cancer cells into the blood stream, with the potential to cause hyperkalemia; hyperphosphatemia and secondary hypocalcemia; hyperuricemia; AKI; and, should usual homeostatic mechanisms fail, death. TLS most commonly follows treatment of hematologic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 24 extracted citations


Publications referenced by this paper.
Showing 1-10 of 97 references

Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome

  • RW Knoebel, LoM, CW Crank
  • J Oncol Pharm Pract
  • 2011

Similar Papers

Loading similar papers…